Hikma Pharmaceuticals Plc Director/PDMR Shareholding (6054R)

TIDMHIK

RNS Number : 6054R

Hikma Pharmaceuticals Plc

15 June 2018

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Surendera Tyagi

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Surendera Tyagi 
 2    Reason for the notification 
 a)   Position/status           Chief Scientific Officer and Global Head of 
                                 R&D 
 b)   Initial notification      Initial notification 
       /Amendment 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                      Hikma Pharmaceuticals PLC 
 b)   LEI                       549300BNS685UXH4JI75 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
 a)   Description of            Description: Ordinary shares of 10 pence each 
       the financial             (Shares) 
       instrument, type          ID Code: GB00B0LCW083 
       of instrument 
       and identification 
       code 
 b)   Nature of the             Market purchase of 1,400 Ordinary Shares by 
       transaction               IG Markets Limited for and on behalf of Surendera 
                                 Tyagi. 
 c)   Price(s) and              Price(s): GBP14.00 
       volume(s)                 Volume(s): 1,400 
 d)   Aggregated information    Volume: 1,400 
                                 Price: GBP19,600.00 
 e)   Date of the transaction   14 June 2018 
 f)   Place of the              London Stock Exchange (XLON) 
       transaction 
 

Peter Speirs

Company Secretary, responsible for releasing this announcement

[phone]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBSGDLDDBBGIU

(END) Dow Jones Newswires

June 15, 2018 10:24 ET (14:24 GMT)